Clinical Trials Arena May 23, 2022
Data Journalism Team

Deals relating to precision and personalized medicine have seen a decrease of 54.1% from H2 2020 to H2 2021.

In the second half of 2021 the number of deals relating to precision and personalized medicine decreased significantly by 54.1% from the same period in 2020.

This marks an acceleration in growth from the 86.7% decrease in deals that occurred in H1 2021 relative to the same period a year earlier.

GlobalData’s deals database looks at mergers, acquisitions and venture capital and private equity investments taking place daily between thousands of companies across the world.

During second half of 2021, deals relating to precision and personalized...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Clinical Trials, Pharma / Biotech, Precision Medicine, Survey / Study, Trends
Challenges in Trial Access and Treatment for Women with Chronic Illnesses
Brainomix AI shows its worth in AZ pulmonary fibrosis trial
Moderna moves three vaccines into final stage trials as it works to rebound from Covid slump
'From Interpretation to Action': Using CGM to Manage T2D
Oncology in 2024: The clinical trial trends reshaping the role of CROs

Share This Article